Search results for Biib

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update - Slideshow

Financial Advisory Corp Buys 252,776 Shares of IBTI

This ETF tracks U.S. Treasury bonds maturing in 2028, providing defined maturity exposure and a portfolio of government-backed securities.

ImmunityBio acquiring U.S. rights to Tokyo strain of BCG

<![CDATA[Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal]]>

<![CDATA[Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals ]]>

Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

Beigene

Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Biogen advances Alzheimer’s tau program despite midphase miss

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the Alzheimer’s disease trial failed to yield the hoped-for dose...

Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biop...

Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqemb...

<![CDATA[FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection ]]>

INVIVYD

INVIVYD Anonymous (not verified) Wed, 04/29/2026 - 14:17 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...

Frexalimab AAN20226

Frexalimab is an indirect B cell inhibitor. It block the natural signal that a B cell gets from T cells and antigen presenting cells as it blocks the ligand (binding bit) to the CD...

BioDelivery Sciences Int’l, Inc. v. Alvogen PB Research & Development LLC

This case was filed in 2018 when Alvogen submitted to the FDA an ANDA for approval to market generic Belbuca, a buprenorphine buccal film used to administer the drug transmucosally...

<![CDATA[Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand St...

<![CDATA[FDA Issues CRL to AbbVie for TrenibotulinumtoxinE’s Biologics License Application ]]>

BeiGene Must Face AbbVie's Chemical Trade Secret Claims

An Illinois federal judge has denied oncological research company BeiGene's request to escape claims from AbbVie Inc. that it poached a retired scientist to obtain trade secrets re...

May 12 2026 - BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

May 12 2026 - BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal admin Tue, 05/12/2026 - 12:10 Big deals lead the way today, with a massive BMS partners...

Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset

Boehringer Ingelheim has put up 407.5 million euros in biobucks to secure global rights to a first‑in‑class antibody Immunitas Therapeutics is developing for chronic inflammatory a...

Spotlight On: Actemra® (tocilizumab) / Tofidence™ (tocilizumab-bavi) / Tyenne® (tocilizumab-aazg) / Avtozma® (tocil...

Tocilizumab Challenged Claim Types in IPRs: Claims are counted in each IPR, so claims from the same patent challenged in multiple IPRs are counted more than once. Within each IPR,...

Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg reboun...

Why Biogen Is Paying $5.6B to Buy Apellis Pharma

Biogen’s Apellis Pharmaceuticals acquisition comes nearly two years after the drugmaker purchased immunology startup Human Immunology Biosciences. CEO Chris Viehbacher said Apellis...